立体定向消融体部放疗治疗不可手术的原发性肾癌:一项前瞻性临床试验
这项前瞻性介入临床试验评估了立体定向消融体部放疗(SABR)用于不适合手术的肾细胞癌(RCC)患者的可行性与安全性。37例患者中89%完成全部处方照射,2年局部无进展率100%、远处无进展率89%、总生存率92%,中位随访24个月。肾小球滤过率从基线均值55 mL/min降至1年和2年的44 mL/min(P < 0.001)。
要点
- SABR治疗不可手术原发性RCC可行(89%完成全部照射)且耐受性良好,未记录4-5级毒性。
- 2年局部无进展率100%、远处无进展率89%、总生存率92%,中位随访24个月。
- 基线中性粒细胞与淋巴细胞比值与1年肿瘤大小变化百分比相关,r²=0.45(P < 0.001)。
核心结论
- 研究结果表明SABR治疗原发性RCC可行且耐受性良好,在不可手术队列中观察到令人鼓舞的肿瘤控制、功能保留和早期生存结局。
- 基线中性粒细胞与淋巴细胞比值可能预测免疫介导的反应,需进一步研究。
研究设计与样本
- 前瞻性介入临床试验,经机构伦理委员会批准,不可手术患者经多学科共识后知情同意入组。
- 共37例患者(中位年龄78岁),其中62%为T1b、35%为T1a、3%为T2a;1例为双侧原发;92%经组织学确诊。
- 患者接受单次26 Gy或三次14 Gy照射,取决于肿瘤大小。
- 33例患者和34个肾脏接受了全部处方SABR分次(可行性89%)。
- 肿瘤反应采用实体瘤疗效评价标准v1.1定义,毒性采用常见不良事件评价标准v4.0记录。
主要发现
- 治疗相关1-2级毒性发生于26例患者(78%),3级毒性1例(3%),未记录4-5级毒性,6例(18%)报告无毒性。
- 2年局部无进展率、远处无进展率和总生存率分别为100%、89%和92%。
- 基线肾小球滤过率均值为55 mL/min,1年和2年降至44 mL/min(P < 0.001)。
- 中性粒细胞与淋巴细胞比值与1年肿瘤大小变化百分比相关,r²=0.45(P < 0.001)。
关键数值与推荐
- 肿瘤反应采用实体瘤疗效评价标准v1.1定义。
- 毒性采用常见不良事件评价标准v4.0记录。
- 照射方案为单次26 Gy或三次14 Gy,取决于肿瘤大小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the feasibility and safety of stereotactic ablative body radiotherapy (SABR) for renal cell carcinoma (RCC) in patients unsuitable for surgery. Secondary objectives were to assess oncological and functional outcomes. MATERIALS AND METHODS: This was a prospective interventional clinical trial with institutional ethics board approval. Inoperable patients were enrolled, after multidisciplinary consensus, for intervention with informed consent. Tumour response was defined using Response Evaluation Criteria In Solid Tumors v1.1. Toxicities were recorded using Common Terminology Criteria for Adverse Events v4.0. Time-to-event outcomes were described using the Kaplan-Meier method, and associations of baseline variables with tumour shrinkage was assessed using linear regression. Patients received either single fraction of 26 Gy or three fractions of 14 Gy, dependent on tumour size. RESULTS: Of 37 patients (median age 78 years), 62% had T1b, 35% had T1a and 3% had T2a disease. One patient presented with bilateral primaries. Histology was confirmed in 92%. In total, 33 patients and 34 kidneys received all prescribed SABR fractions (89% feasibility). The median follow-up was 24 months. Treatment-related grade 1-2 toxicities occurred in 26 patients (78%) and grade 3 toxicity in one patient (3%). No grade 4-5 toxicities were recorded and six patients (18%) reported no toxicity. Freedom from local progression, distant progression and overall survival rates at 2 years were 100%, 89% and 92%, respectively. The mean baseline glomerular filtration rate was 55 mL/min, which decreased to 44 mL/min at 1 and 2 years (P < 0.001). Neutrophil:lymphocyte ratio correlated to % change in tumour size at 1 year, r2 = 0.45 (P < 0.001). CONCLUSION: The study results show that SABR for primary RCC was feasible and well tolerated. We observed encouraging cancer control, functional preservation and early survival outcomes in an inoperable cohort. Baseline neutrophil:lymphocyte ratio may be predictive of immune-mediated response and warrants further investigation.
引用
- Siva S, Pham D, Kron T, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017. PMID: 28188682. doi:10.1111/bju.13811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。